Cyclophosphamide-idarubicin-dexamethasone An effective oral combination chemotherapy for melphalan-prednisolone resistant multiple myeloma
Majumdar, G.; Ganguly, K.; Kashyap, S.; Bardhan, G.
British Journal of Haematology 102(1): 352
1998
ISSN/ISBN: 0007-1048
Accession: 030771989
PDF emailed within 1 workday: $29.90
Related References
Kashyap, S.; Ganguly, K.; Bardhan, G.; Majumdar, G. 1999: Low dose oral idarubicin in combination with cyclophosphamide and dexamethasone (CID) for management of melphalan-prednisolone (MP) resistant myeloma Leukemia and Lymphoma 33(3-4): 407-408Shimizu, K.; Kamiya, O.; Hamajima, N.; Mizuno, H.; Kobayashi, M.; Hirabayashi, N.; Takeyama, H.; Kato, R.; Kawashima, K.; Nitta, M. 1990: Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage IIi myeloma. the Nagoya Myeloma Cooperative Study Group Japanese Journal of Cancer Research: Gann 81(12): 1320-1327
Takagi, T.; Oguro, M.; Sakai, C. 1986: Combination chemotherapy with melphalan, cyclophosphamide, vincristine, ACNU and prednisolone (MEV(Ac)P) for multiple myeloma Japanese Journal of Clinical Hematology 27(12): 2249-2253
Shimizu K.; Kamiya O.; Hamajima N.; Mizuno H.; Kobayashi M.; Hirabayashi N.; Takeyama H.; Kato R.; Kawashima K.; Et Al 1990: Multi drug combination therapy with vincristine melphalan cyclophosphamide prednisolone was more effective than cyclophosphamide prednisolone in stage iii myeloma Japanese Journal of Cancer Research 81(12): 1320-1326
Kazuyuki Shimizu; Osamu Kamiya; Nobuyuki Hamajima; Harumitsu Mizuno; Masahide Kobayashi; Noriyuki Hirabayashi; Hideo Takeyama; Ryoichi Kato; Kohei Kawashima; Masakazu Nitta; Tomomitsu Hotta; Makoto Utsumi; Eiichi Nagura 1990: Multi-drug Combination Therapy with Vincristine-Melphalan-Cyclophosphamide-Prednisolone Was More Effective than Cyclophosphamide-Prednisolone in Stage III Myeloma Cancer Science 81(12): 1320-1327
Glueck, S.; Schoppe, W.D.; Schneider, W. 1986: Vincristine cyclophosphamide melphalan prednisolone chemotherapy of multiple myeloma after ineffective melphalan prednisolone therapy Blut 53(3): 227
Chou, T.; Tobinai, K.; Uike, N.; Asakawa, T.; Saito, I.; Fukuda, H.; Mizoroki, F.; Ando, K.; Iida, S.; Ueda, R.; Tsukasaki, K.; Hotta, T.; Aikawa, K.; Matsuda, S.; Nakata, M.; Oshimi, K.; Ohmachi, K.; Ohnishi, K.; Kinoshita, T.; Okamura, S.; Tsukada, J. 2011: Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112 Japanese Journal of Clinical Oncology 41(4): 586-589
Peest, D.; Schmoll, H.J.; Schedel, I.; Deicher, H.; Boll, I.; Essers, U.; Gamm, H.; Glueck, S.; Goerg, K.; E.A. 1986: Melphalan and prednisolone vs. vincristine cyclophosphamide melphalan and prednisolone a prospective randomized trial in stage ii and iii multiple myeloma Journal of Cancer Research and Clinical Oncology 111(Suppl): S8
Uzuka, Y.; Saito, Y.; Takahashi, H.; Komatsu, M.; Ito, T. 1989: Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(6): 2269-2273
Ballester, O.F.; Moscinski, L.C.; Fields, K.K.; Hiemenz, J.W.; Zorsky, P.E.; Goldstein, S.C.; Saba, H.I.; Spiers, A.S.; Kronish, L.; Sullivan, P.; Elfenbein, G.J. 1997: Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma British Journal of Haematology 96(4): 746-748
Ishii, H. 1988: Combination chemotherapy for multiple myeloma with melphalan, ifosfamide, prednisolone, nitrosourea and vincristine Acta Medica Okayama 42(3): 175-182
Kyriakou, C.; Thomson, K.; D'Sa, S.; Flory, A.; Hanslip, J.; Goldstone, A.H.; Yong, K.L. 2005: Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma British Journal of Haematology 129(6): 763-770
Suzuki, K.; Doki, N.; Meguro, K.; Sunami, K.; Kosugi, H.; Sasaki, O.; Takagi, T.; Murakami, H.; Shimizu, K. 2019: Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation International Journal of Hematology 110(4): 447-457
Adachi, T.; Asano, K.; Sezaki, T.; Takahashi, I.; Kimura, I. 1982: Prognostic factors in multiple myeloma treated with prednisolone and sequential melphalan and ifosfamide: MIP combination chemotherapy Acta Medica Okayama 36(1): 39-47
Gregory, W.M.; Richards, M.A.; Malpas, J.S. 1992: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 10(2): 334-342